Table 2.
Effects of DHA administration on hepatic fatty acid ratios in healthy and cirrhotic rats.
| Ratios | Healthy Vehicle |
Healthy DHA |
Cirrhotic Vehicle |
Cirrhotic DHA |
|---|---|---|---|---|
| SFA/MUFA | 2.86 ± 0.44 | 3.27 ± 0.48 | 1.81 ± 0.34 ### | 3.04 ± 0.30 *** |
| MUFA/PUFA | 0.32 ± 0.06 | 0.26 ± 0.03 | 0.58 ± 0.13 ## | 0.32 ± 0.03 *** |
| ω-6/ω-3 | 5.32 ± 0.88 | 2.72 ± 0.46 ** | 11.72 ± 1.56 ### | 2.01 ± 0.26 *** |
|
ω-3 INDEX
(DHA + EPA) |
6.03 ± 1.09 | 11.15 ± 1.64 *** | 2.08 ± 0.57 ### | 12.95 ± 1.49 *** |
| AA/EPA | 108.3 ± 25.2 | 12.74 ± 5.69 *** | 156.0 ± 24.2 ### | 8.65 ± 2.35 *** |
| AA/DHA | 3.26 ± 0.58 | 1.50 ± 0.33 *** | 7.87 ± 1.41 ### | 0.90 ± 0.18 *** |
|
Δ5
(C20:4 n-6/C20:3 n-6) |
36.99 ± 3.95 | 17.39 ± 1.152 *** | 47.55 ± 2.12 | 12.09 ± 0.85 *** |
|
Δ6
(C20:3 n-6/C18:2 n-6) |
2.99 ± 0.31 | 4.58 ± 0.27 | 1.76 ± 0.10 | 4.76 ± 0.31 *** |
|
SCD1 INDEX
(C16:1 n-7/C18:1 n-9) |
20.72 ± 1.81 | 22.98 ± 2.79 | 16.80 ± 1.33 | 19.74 ± 1.51 |
|
SCD16 INDEX
(C16:1 n-7/C16:0) |
8.24 ± 0.81 | 7.73 ± 0.78 | 11.30 ± 1.17 | 7.08 ± 0.49 |
|
SCD18 INDEX
(C18:1 n-9/C18:0) |
47.32 ± 3.70 | 42.72 ± 3.76 | 111.6 ± 14.1 ### | 56.02 ± 2.63 *** |
| C18:2 n-6/C20:4 n-6 | 0.95 ± 0.02 | 1.29 ± 0.08 | 1.24 ± 0.09 | 1.71 ± 0.08 |
| C18:0/C16:0 | 0.85 ± 0.01 | 0.81 ± 0.04 | 0.62 ± 0.05 # | 0.66 ± 0.03 |
| C24:0/C22:0 | 2.82 ± 0.12 | 3.39 ± 0.20 | 2.53 ± 0.22 | 3.01 ± 0.12 |
| C24:0/C20:0 | 7.77 ± 0.73 | 7.28 ± 0.58 | 3.90 ± 0.35 # | 5.73 ± 0.35 |
| C18:1 n-7/C16:1 n-7 | 2.22 ± 0,18 | 1.92 ± 0.23 | 1.34 ± 0.17 | 1.67 ± 0.11 ** |
Results are expressed as mean ± S.E.M. n = 5 for healthy animals and n = 11 for cirrhotic animals. # <0.05; ## <0.01; ## <0.001 vs. healthy vehicle group and * <0.05; ** <0.01; *** <0.001 vs. corresponding group receiving vehicle. AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid; SFA, saturated fatty acid.